PG4
Alternative Names: PG4 pneumococcal vaccineLatest Information Update: 29 Nov 2025
At a glance
- Originator Pfizer
- Class Antivirals; Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Pneumococcal infections
Most Recent Events
- 30 Jul 2025 Phase-II clinical trials in Pneumococcal infections (Prevention, In infants) in USA and Puerto Rico (Injection) (NCT06531538)
- 22 Jul 2025 Phase-I clinical trials in Pneumococcal infections (Prevention, In adults, In the elderly) in USA (Injection) (NCT07086677)